北京市京轩律师事务所 关于哈尔滨誉衡药业股份有限公司 2023 年年度股东大会的法律意见书 致哈尔滨誉衡药业股份有限公司： 根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》（以下简称"《证券法》"）及中国证券 监督管理委员会《上市公司股东大会规则》（以下简称"《股东大会 规则》"）等法律、法规和规范性文件的规定及《哈尔滨誉衡药业股 份有限公司章程》(以下简称"《公司章程》")的有关规定，北京市 京轩律师事务所（以下简称"本所"）受哈尔滨誉衡药业股份有限公 司（以下简称"公司"）的委托，指派律师参加了公司 2023 年年度 股东大会并就有关事宜出具本法律意见书。 为出具本法律意见书，本所指派律师列席了公司本次股东大会并 审查了公司提供的关于召开本次股东大会的有关文件资料。本所律师 声明如下： 1、公司应当对向本所律师提供的本次股东大会会议资料以及其 他相关资料（包括但不限于董事会决议、关于召开本次股东大会的公 告、本次股东大会股权登记日的《股东名册》等）的真实性、完整性 和有效性负责。 2、按照《股东大会规则》的要求，本所律师仅对本次股东大会 的召集、召开程序、本次股东大会召集 ...

Financial Performance - The company's operating revenue for Q1 2024 was ¥593,133,301.68, a decrease of 12.92% compared to ¥681,168,970.96 in the same period last year[3]. - Net profit attributable to shareholders increased by 160.65% to ¥52,282,909.59 from ¥20,058,598.74 year-on-year[3]. - Basic and diluted earnings per share increased by 158.24% to ¥0.0235 from ¥0.0091 in the same period last year[3]. - The total operating revenue for the current period is ¥593,133,301.68, a decrease of approximately 12.92% compared to ¥681,168,970.96 in the previous period[20]. - The net profit for the current period is CNY 55,761,035.49, a significant increase from CNY 21,870,444.70 in the previous period, representing a growth of approximately 154%[21]. - The total comprehensive income attributable to the parent company is CNY 52,354,237.76, compared to CNY 19,344,563.25 in the previous period, representing an increase of approximately 171%[21]. - The operating profit for the current period is CNY 68,449,052.90, up from CNY 32,216,202.85 in the previous period, reflecting an increase of approximately 113%[21]. Cash Flow and Investments - The net cash flow from operating activities rose by 90.25% to ¥159,239,649.03, compared to ¥83,699,367.15 in the previous year[9]. - The net cash flow from investing activities was negative at -¥4,756,664.99, a decline of 118.92% compared to ¥25,147,232.08 in the previous year[9]. - The company experienced a net cash outflow from investing activities of CNY 4,756,664.99, contrasting with a net inflow of CNY 25,147,232.08 in the previous period[22]. - The net cash outflow from financing activities was CNY 164,988,138.09, compared to a net outflow of CNY 101,258,939.96 in the previous period, indicating a worsening cash flow situation[23]. Assets and Liabilities - Total assets at the end of the reporting period were ¥3,079,864,778.97, a decrease of 2.30% from ¥3,152,450,105.19 at the end of the previous year[3]. - Current liabilities decreased significantly to ¥1,168,200,638.82 from ¥1,412,228,273.02, a reduction of about 17.24%[18]. - The company's cash and cash equivalents at the end of the period are ¥700,893,734.65, down from ¥711,275,270.60, a decrease of approximately 1.06%[17]. - The cash and cash equivalents at the end of the period decreased to CNY 700,607,124.37 from CNY 1,237,435,456.33, a decline of about 43.4%[23]. Shareholder Equity and Stock - Shareholders' equity attributable to the parent company increased by 8.83% to ¥1,808,476,235.24 from ¥1,661,773,347.48 at the end of the previous year[3]. - The company's total number of ordinary shareholders at the end of the reporting period was 99,096[11]. - As of March 2024, the company's total share capital increased from 2,198,122,950 shares to 2,270,513,950 shares due to the completion of the 2024 restricted stock incentive plan[12]. - The company granted 72.391 million shares of restricted stock to 105 incentive targets, accounting for 3.29% of the total share capital at the time of the announcement[15]. - As of March 2024, the total shares held by Shen Zhenyu and her concerted actions amounted to 208.2724 million shares, representing a holding ratio of 9.17%[13]. Government Subsidies and Financial Expenses - The company received government subsidies amounting to ¥38,864,209.88, a significant increase of 355.03% compared to ¥8,540,930.78 in the previous year[8]. - Financial expenses decreased by 91.44% to ¥1,324,953.12 from ¥15,480,627.57 due to repayment of bank loans[8]. - The company received government subsidies amounting to RMB 28.1269 million, impacting the net profit attributable to shareholders by RMB 22.7125 million[14]. - The company reported a decrease in financial expenses to ¥1,324,953.12 from ¥15,480,627.57, a significant reduction of about 91.45%[20]. Research and Development - Research and development expenses for the current period are ¥14,704,935.33, compared to ¥13,997,253.96 in the previous period, representing an increase of approximately 5.06%[20]. Product Development and Market Competitiveness - The product Fluorobiphenyl Ester Injection won the bid for centralized procurement in 13 provinces in Guangdong and obtained incremental qualifications[14]. - The company signed a contract to acquire the marketing authorization for the drug Sitagliptin Metformin Sustained-Release Tablets, which received approval in February 2024[15]. - The shelf life of Potassium Chloride Sustained-Release Tablets was extended from 24 months to 36 months, enhancing market competitiveness[15]. - The company reported a fair value loss of RMB 11.4057 million from equity investments, an increase in loss of RMB 9.5803 million compared to the previous year[14].

哈尔滨誉衡药业股份有限公司 内部控制审计报告 上会师报字(2024)第 5003 号 上会会计师事务所（特殊普通合伙） 中国 上海 计师 李务所(特殊善通合伙) l Public Accountants (Special General 内部控制审计报告 上会师报字(2024)第 5003 号 哈尔滨誉衡药业股份有限公司全体股东: 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求,我们 审计了哈尔滨誉衡药业股份有限公司(以下简称"贵公司")2023 年 12月 31 日的财务 报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部控制评 价指引》的规定,建立健全和有效实施内部控制,并评价其有效性是贵公司董事会 的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上,对财务报告内部控制的有效性发表审 计意见,并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部控制的固有局限性 内部控制具有固有局限性,存在不能防止和发现错报的可能性。此外,由于情 况的变化可能导致内部控制变得不恰当,或对控制政策和程序遵循的程度降低,根 ...

哈尔滨誉衡药业股份有限公司 哈尔滨誉衡药业股份有限公司 章 程 （2024 年 4 月修订） | 第一章 | 总则 3 | | --- | --- | | 第二章 | 经营宗旨和范围 5 | | 第三章 | 股份 5 | | | 第一节 股份发行 5 | | | 第二节 股份增减和回购 6 | | | 第三节 股份转让 7 | | 第四章 | 股东和股东大会 8 | | 第一节 | 股东 8 | | | 第二节 股东大会的一般规定 11 | | | 第三节 股东大会的召集 14 | | | 第四节 股东大会的提案与通知 16 | | 第五节 | 股东大会的召开 18 | | | 第六节 股东大会的表决和决议 21 | | 第五章 | 董事会 25 | | | 第一节 董事 25 | | | 第二节 董事会 29 | | | 第三节 董事会秘书 34 | | 第六章 | 总经理及其他高级管理人员 35 | | 第七章 | 监事会 37 | | | 第一节 监事 37 | | | 第二节 监事会 38 | | | 第三节 监事会决议 40 | | 第八章 | 财务会计制度、利润分配和审计 41 | | 第一节 | ...

哈尔滨誉衡药业股份有限公司 关于公司独立董事、副总经理辞职的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2024 年 4 月 18 日，哈尔滨誉衡药业股份有限公司（以下简称"公司"）董 事会收到独立董事姜明辉女士及副总经理王然先生提交的书面辞呈。 姜明辉女士因个人原因，申请辞去公司独立董事、薪酬与考核委员会主任委 员及提名委员会委员职务，辞职后，将不再担任公司任何职务。截至目前，姜明 辉女士未持有公司股票。 鉴于姜明辉女士的离职将导致公司独立董事低于《公司章程》规定的独立董 事人数，姜明辉女士将继续按照相关法律、法规和《公司章程》的规定履行独立 董事的职责。 根据公司第六届董事会第十三次会议审议通过的《关于修订<公司章程>的 议案》，公司董事会将调整为 6 人（尚须经 2023 年年度股东股东大会批准）， 届时，现有独立董事可满足《公司章程》及相关法律、法规的人数要求。 哈尔滨誉衡药业股份有限公司 证券代码：002437 证券简称：誉衡药业 公告编号：2024-040 鉴于上述，姜明辉女士的辞职申请将于公司 2023 年年度股东大会批准《公 司章程》 ...

哈尔滨誉衡药业股份有限公司 证券代码：002437 证券简称：誉衡药业 公告编号：2024-044 哈尔滨誉衡药业股份有限公司 关于拟续聘上会会计师事务所（特殊普通合伙） 担任公司 2024 年外部审计机构的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次不涉及会计师事务所的变更。 第 1 页 ⑴ 会计师事务所名称：上会会计师事务所（特殊普通合伙） ⑵ 组织形式：特殊普通合伙企业 ⑶ 注册地址：上海市静安区威海路 755 号 25 层 ⑷ 成立日期：2013 年 12 月 27 日 ⑸ 人员信息 哈尔滨誉衡药业股份有限公司 人。 ⑹ 审计收入及服务客户情况 上会事务所 2023 年度审计的收入总额为 7.06 亿元（币种：人民币，下同）， 审计业务收入为 4.64 亿元、证券业务收入为 2.11 亿元。上市公司审计客户共 68 家，主要行业：采矿业；制造业；电力、热力、燃气及水生产和供应业；批发和 零售业；交通运输、仓储和邮政业；房地产业；信息传输、软件和信息技术服务 业；科学研究和技术服务业；文化、体育和娱乐业；水利、环境和公共设施 ...

Product Development and Innovation - In 2023, the company submitted 12 new product applications for market approval, indicating a strong focus on product development[5] - Sales of the product "Lixisenatide Metformin Sustained-Release Tablets" in collaboration with Anbisen received approval in February 2024, showcasing successful product development efforts[5] - The company plans to deepen its "Product First" strategy and increase R&D investment in 2024[8] - The company is actively conducting consistency evaluation for its existing products, including injection of levoleucovorin calcium and cyclophosphamide, with 2 consistency evaluation project submissions completed by the report date[55] - The company has submitted registration materials for 10 products under development as of the report date, focusing on differentiated generic drugs and products with unexpired patents[56] - The company signed cooperation agreements for 6 projects, including "Sitagliptin and Metformin Sustained-Release Tablets," which is expected to receive drug approval by February 2024[57] - The company is focusing on expanding its product line through mergers, acquisitions, and independent research and development to enhance its market presence[48] Financial Performance - The company's operating revenue for 2023 was ¥2,626,039,306.71, a decrease of 15.51% compared to ¥3,107,945,160.60 in 2022[31] - The net profit attributable to shareholders for 2023 was ¥120,334,186.37, a significant turnaround from a loss of ¥291,328,832.92 in 2022, representing a 141.31% increase[31] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥53,377,327.33, improving by 117.53% from a loss of ¥304,466,519.92 in the previous year[31] - The basic earnings per share for 2023 was ¥0.0547, compared to a loss of ¥0.1325 in 2022, marking a 141.28% increase[31] - The total assets at the end of 2023 were ¥3,152,450,105.19, down 22.62% from ¥4,074,185,955.01 at the end of 2022[31] - The net assets attributable to shareholders increased by 1.87% to ¥1,661,773,347.48 at the end of 2023, compared to ¥1,631,237,579.41 at the end of 2022[31] - The company reported a cash flow from operating activities net amount of ¥274,175,284.57, an increase of 4.80% from ¥261,615,607.78 in 2022[31] - The weighted average return on equity for 2023 was 7.26%, a significant improvement from -16.55% in 2022, reflecting a 23.81% increase[31] Cost Management and Efficiency - The company achieved a reduction in financial expenses by CNY 15.43 million, optimizing its asset-liability structure with a debt ratio decrease from 58% at the end of 2022 to 46% at the end of 2023[7] - Management expenses were reduced by CNY 37.61 million through detailed cost-cutting measures[7] - The company aims to enhance operational efficiency through organizational restructuring and improved management mechanisms[8] - The company has initiated a stock incentive plan to support its strategic goals and enhance employee motivation[8] - The company is enhancing its sales network by increasing investment in secondary markets and developing county-level hospitals to expand market reach[53] Market Position and Share - The company maintained a leading market share of over 80% for its injection of multiple vitamins, which is a domestic first imitation and a unique product[49] - The market share for the product Ginkgo Biloba Injection reached 45.60%, making it the top product in its segment as of mid-2023[49] - The potassium chloride sustained-release tablets achieved a market share of 37.06%, ranking second in its segment[49] - The company was ranked 46th in the 2022 China Pharmaceutical Industry Top 100 list, reflecting its competitive position in the industry[49] Governance and Management Changes - The company has undergone a change in its controlling shareholder status, becoming a company without a controlling shareholder as of April 2023[30] - The company has established a complete and independent governance structure, including a board of directors and supervisory board, in compliance with the Company Law[123] - The company has experienced personnel changes, including the resignation of key executives for personal reasons during the reporting period[129] - The company experienced significant management changes, with multiple resignations including the Chairman of the Supervisory Board and the General Manager, all citing personal reasons for their departures[130] - New appointments include Wang Xiaohang as Vice General Manager and Li Runbao as Vice General Manager, indicating a restructuring within the management team[130] Research and Development - The company's R&D expenses for 2023 were CNY 85,438,221.66, a decrease of 15.10% from CNY 100,630,375.22 in 2022[74] - Research and development (R&D) investment amounted to CNY 89.16 million, a decrease of 12.26% from CNY 101.62 million in 2022, while the R&D investment as a percentage of operating revenue increased to 3.40% from 3.27%[78] - The number of R&D personnel decreased by 10.00% to 90 in 2023, with a notable increase of 25.00% in the number of personnel under 30 years old[75] Environmental and Social Responsibility - The company strictly adheres to environmental protection laws and regulations, including the Environmental Protection Law and the Air Pollution Prevention and Control Law[163] - Wastewater treatment facilities for Pud Pharmaceutical, Leibotong, and Yuheng Pharmaceutical are operating normally, with detailed discharge concentrations and total amounts provided in the report[165] - The company actively promotes the sharing of interests with stakeholders and integrates social responsibility into all aspects of its development[167] - The company emphasizes employee rights protection and development, ensuring a safe working environment and providing comprehensive care for employees[169] Risks and Challenges - The company is facing industry policy risks that may impact product sales and pricing due to regulatory changes in the pharmaceutical sector[104] - The company acknowledges the risk of drug development failures due to increasing regulatory requirements and funding needs[106] - The company will implement strict quality control measures throughout the drug production process to minimize quality risks[107] Internal Control and Compliance - The company has established a comprehensive internal control framework to ensure the accuracy of financial reporting[158] - The internal control audit report issued a standard unqualified opinion, confirming effective internal controls related to financial statements as of December 31, 2023[160] - The company has not reported any significant internal control deficiencies during the reporting period[157] Employee Development and Compensation - The company has established a differentiated compensation system based on market attractiveness and internal talent retention, focusing on management, production, marketing, R&D, and functional sequences[150] - Employee benefits include customized commercial supplementary medical insurance, employer liability insurance, group life insurance, and accident transportation insurance to enhance employee satisfaction[151] - A talent development project has been initiated to identify and cultivate high-potential young leaders, enhancing their comprehensive capabilities for future company growth[153]

哈尔滨誉衡药业股份有限公司 哈尔滨誉衡药业股份有限公司 募集资金使用管理制度 第一章 总则 第一条 为规范哈尔滨誉衡药业股份有限公司（以下简称"公司"）募集资金 管理，提高募集资金使用效率，根据《公司法》、《证券法》、《上市公司监管指引 第 2 号——上市公司募集资金管理和使用的监管要求》、《深圳证券交易所股票上 市规则》（以下简称"《股票上市规则》"）、《深圳证券交易所上市公司自律监 管指引第 1 号——主板上市公司规范运作》（以下简称"《规范运作指引》"） 等有关法律、法规、规章、规范性文件和《公司章程》的有关规定，特制定本制 度。 第二条 本制度所称募集资金是指公司通过公开发行证券（包括首次公开发 行股票、配股、增发、发行可转换公司债券、发行分离交易的可转换公司债券、 发行权证等）以及非公开发行股票向投资者募集并用于特定用途的资金。 第三条 公司募集资金到位后，公司应及时办理验资手续，由具有证券从业 资格的注册会计师事务所出具验资报告。 第四条 公司董事会负责建立健全募集资金管理制度，对募集资金专户存储、 使用、变更、监督和责任追究等内容进行明确规定，并确保该制度的有效实施。 第五条 公司募集资金投资项 ...

哈尔滨誉衡药业股份有限公司 审计报告 上会师报字(2024)第 4956 号 上会会计师事务所（特殊普通合伙） 中国 上海 一师 事务所(特殊善通合伙) lic Sccountants (Special General 审计报告 上会师报字(2024)第 4956 号 哈尔滨誉衡药业股份有限公司全体股东: 一、审计意见 我们审计了哈尔滨誉衡药业股份有限公司(以下简称"誉衡药业")财务报表, 包括 2023年 12 月 31 日的合并及公司资产负债表,2023 年度的合并及公司利润表、 合并及公司现金流量表、合并及公司所有者权益变动表以及相关财务报表附注。 我们认为,后附的财务报表在所有重大方面按照企业会计准则的规定编制,公 允反映了誉衡药业 2023 年 12 月 31 日的合并及公司财务状况以及 2023 年度的合并及 公司经营成果和现金流量。 二、形成审计意见的基础 我们按照中国注册会计师审计准则的规定执行了审计工作。审计报告的"注册 会计师对财务报表审计的责任"部分进一步阐述了我们在这些准则下的责任。按照 中国注册会计师职业道德守则,我们独立于誉衡药业,并履行了职业道德方面的其 他责任。我们相信,我们获 ...

哈尔滨誉衡药业股份有限公司 证券代码：002437 证券简称：誉衡药业 公告编号：2024-033 哈尔滨誉衡药业股份有限公司 关于提请 2023 年年度股东大会授权董事会 办理小额快速融资相关事宜的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2024 年 4 月 18 日，哈尔滨誉衡药业股份有限公司（以下简称"公司"）第 六届董事第十三次会议审通过了《关于提请 2023 年年度股东大会授权董事会办 理小额快速融资相关事宜的议案》，具体情况如下： 一、关于提请 2023 年年度股东大会授权董事会办理小额快速融资的相关事 宜 根据《上市公司证券发行注册管理办法》、《深圳证券交易所上市公司证券 发行上市审核规则》、《深圳证券交易所上市公司证券发行与承销业务实施细则》 等相关规定，公司董事会提请 2023 年年度股东大会授权董事会决定向特定对象 发行融资总额不超过人民币 3 亿元且不超过最近一年末净资产 20%的股票，授权 期限为 2023 年度股东大会通过之日起至 2024 年度股东大会召开之日止。本次授 权事宜包括以下内容： 1、确认公司是否符合以简易 ...